Description
Tirz is a first-in-class “dual agonist” medication that targets both GLP-1 and GIP metabolic hormone receptors simultaneously. By combining appetite suppression with enhanced fat-metabolism signaling, it delivers significantly greater weight loss and glycemic control than single-receptor GLP-1 drugs like Semaglutide. Administered once weekly via subcutaneous injection, it is FDA-approved for the treatment of type 2 diabetes and chronic weight management.
Reviews
There are no reviews yet.